149 related articles for article (PubMed ID: 36577021)
1. Plasmablastic lymphoma: from genetics to treatment.
Frontzek F; Hailfinger S; Lenz G
Leuk Lymphoma; 2023 Apr; 64(4):799-807. PubMed ID: 36577021
[TBL] [Abstract][Full Text] [Related]
2. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
[TBL] [Abstract][Full Text] [Related]
3. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.
Frontzek F; Staiger AM; Zapukhlyak M; Xu W; Bonzheim I; Borgmann V; Sander P; Baptista MJ; Heming JN; Berning P; Wullenkord R; Erdmann T; Lutz M; Veratti P; Ehrenfeld S; Wienand K; Horn H; Goodlad JR; Wilson MR; Anagnostopoulos I; Lamping M; Gonzalez-Barca E; Climent F; Salar A; Castellvi J; Abrisqueta P; Menarguez J; Aldamiz T; Richter J; Klapper W; Tzankov A; Dirnhofer S; Rosenwald A; Mate JL; Tapia G; Lenz P; Miething C; Hartmann W; Chapuy B; Fend F; Ott G; Navarro JT; Grau M; Lenz G
Nat Commun; 2021 Aug; 12(1):5183. PubMed ID: 34465776
[TBL] [Abstract][Full Text] [Related]
4. Plasmablastic lymphoma: current knowledge and future directions.
Li JW; Peng HL; Zhou XY; Wang JJ
Front Immunol; 2024; 15():1354604. PubMed ID: 38415257
[TBL] [Abstract][Full Text] [Related]
5. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.
Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A
Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914
[TBL] [Abstract][Full Text] [Related]
7. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.
Meer S; Perner Y; McAlpine ED; Willem P
Histopathology; 2020 Jan; 76(2):212-221. PubMed ID: 31361906
[TBL] [Abstract][Full Text] [Related]
8. Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis.
Harmon CM; Smith LB
Arch Pathol Lab Med; 2016 Oct; 140(10):1074-8. PubMed ID: 27684979
[TBL] [Abstract][Full Text] [Related]
9. Plasmablastic lymphoma: An update.
Bailly J; Jenkins N; Chetty D; Mohamed Z; Verburgh ER; Opie JJ
Int J Lab Hematol; 2022 Sep; 44 Suppl 1(Suppl 1):54-63. PubMed ID: 36074710
[TBL] [Abstract][Full Text] [Related]
10. High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma.
Miao L; Guo N; Feng Y; Rao H; Wang F; Huang Q; Huang Y
Histopathology; 2020 Jan; 76(2):201-211. PubMed ID: 31348551
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and genetic landscape of plasmablastic lymphoma in Taiwan.
Chen BJ; Hsieh TH; Yuan CT; Wang RC; Yang CF; Chuang WY; Su YZ; Ho CH; Lin CH; Chuang SS
Pathol Res Pract; 2024 Jan; 253():155059. PubMed ID: 38160484
[TBL] [Abstract][Full Text] [Related]
13. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Loghavi S; Gomez Mediavilla A; Tonda R; Beltran S; Gut M; Pereña Gonzalez A; d'Ámore E; Visco C; Khoury JD; Montes-Moreno S
Haematologica; 2021 Apr; 106(4):1120-1128. PubMed ID: 32273478
[TBL] [Abstract][Full Text] [Related]
14. Transformation of double-hit follicular lymphoma to plasmablastic lymphoma: a partial role of MYC gene rearrangement.
Ise M; Kageyama H; Ikebe D; Araki A; Kumagai K; Itami M
J Clin Exp Hematop; 2018 Sep; 58(3):128-135. PubMed ID: 30012920
[TBL] [Abstract][Full Text] [Related]
15. [Plasmablastic lymphoma].
Fernández-Álvarez R; Sancho JM; Ribera JM
Med Clin (Barc); 2016 Nov; 147(9):399-404. PubMed ID: 27576534
[TBL] [Abstract][Full Text] [Related]
16. MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry.
Pather S; Mashele T; Willem P; Patel M; Perner Y; Motaung M; Nagiah N; Waja F; Philip V; Lakha A; Hale MJ
Histopathology; 2021 Jul; 79(1):86-95. PubMed ID: 33450085
[TBL] [Abstract][Full Text] [Related]
17. Primary CNS plasmablastic lymphoma in an HIV/EBV negative patient: A case report.
Romero M; González-Fontal GR; Saavedra C; Guerra J; Quintero G; Quijano S; Ney D; Henao-Martínez AF
Diagn Cytopathol; 2016 Jan; 44(1):61-5. PubMed ID: 26468050
[No Abstract] [Full Text] [Related]
18. Plasmablastic lymphomas show restricted EBV latency profile and
Ramburan A; Kriel R; Govender D
Leuk Lymphoma; 2022 Feb; 63(2):370-376. PubMed ID: 34612761
[TBL] [Abstract][Full Text] [Related]
19. CD3-positive plasmablastic lymphoma reported in two cases: A potential diagnostic caveat.
Wong YP; Masir N; Chew MX
Indian J Pathol Microbiol; 2021; 64(3):579-583. PubMed ID: 34341278
[TBL] [Abstract][Full Text] [Related]
20. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.
Montes-Moreno S; Martinez-Magunacelaya N; Zecchini-Barrese T; Villambrosía SG; Linares E; Ranchal T; Rodriguez-Pinilla M; Batlle A; Cereceda-Company L; Revert-Arce JB; Almaraz C; Piris MA
Mod Pathol; 2017 Jan; 30(1):85-94. PubMed ID: 27687004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
